Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovas- cular disease burden: the Framingham Heart Study. Eur Heart J. 2009;30:850 856. doi: 10.1093/eurheartj/ehn573. 215. Khawaja T, Greer C, Chokshi A, Chavarria N, Thadani S, Jones M, Schaefle K, Bhatia K, Collado JE, Shimbo D, Einstein AJ, Schulze PC. Epicardial fat volume in patients with left ventricular systolic dysfunction. Am J Cardiol. 2011;108:397 401. doi: 10.1016/j. amjcard.2011.03.058. 216. Doesch C, Suselbeck T, Leweling H, Fluechter S, Haghi D, Schoenberg SO, Borggrefe M, Papavassiliu T. Bioimpedance analy- sis parameters and epicardial adipose tissue assessed by cardiac magnetic resonance imaging in patients with heart failure. Obesity (Silver Spring). 2010;18:2326 2332. doi: 10.1038/oby.2010.65. 217. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925 1932. doi: 10.1016/j.jacc.2008.12.068. 218. von Haehling S, Horwich TB, Fonarow GC, Anker SD. Tipping the scale: heart failure, body mass index, and prognosis. Circulation. 2007;116:588 590. doi: 10.1161/CIRCULATIONAHA. 107.716662. 219. Aquilani R, Opasich C, Verri M, Boschi F, Febo O, Pasini E, Pastoris O. Is nutritional intake adequate in chronic heart failure patients? J Am Coll Cardiol. 2003;42:1218 1223. 220. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb- Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chron- ic heart failure [published correction appears in Lancet. S0140-6736(96)07015-8. 221. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epi- demiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004;43:1439 1444. doi: 10.1016/j.jacc.2003.11.039. 222. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol. 2006;47:85 90. doi: 10.1016/j.jacc.2005.08.050. 223. Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL Jr. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J. 2005;149:744 750. doi: 10.1016/j.ahj.2004.07.010. 224. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic pep- tide levels. Circulation. 2004;109:594 600. doi: 10.1161/01. CIR.0000112582.16683.EA. 225. Sarzani R, Dess -Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest. 1996;19:581 585. 226. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysi- ology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968 976. doi: 10.1161/01.ATV. 0000216787.85457.f3. 227. Gray LJ, Cooper N, Dunkley A, Warren FC, Ara R, Abrams K, Davies MJ, Khunti K, Sutton A. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obes Rev. 2012;13:483 498. doi: 10.1111/j.1467-789X.2011.00981.x. 228. Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, McCullough PA, Ren Fielding C, Franklin BA; on behalf of the American Heart Association Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123:1683 1701. doi: 10.1161/CIR.0b013e3182149099. 229. Goodpaster BH, Delany JP, Otto AD, Kuller L, Vockley J, South- Paul JE, Thomas SB, Brown J, McTigue K, Hames KC, Lang W, Jakicic JM. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA. 2010;304:1795 1802. doi: 10.1001/jama.2010.1505. 230. O Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Pi a IL; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1439 1450. doi: 10.1001/jama.2009.454. 231. Laddu D, Dow C, Hingle M, Thomson C, Going S. A review of evidence-based strategies to treat obesity in adults. Nutr Clin Pract. 2011;26:512 525. doi: 10.1177/0884533611418335. 232. Owan T, Avelar E, Morley K, Jiji R, Hall N, Krezowski J, Gallagher J, Williams Z, Preece K, Gundersen N, Strong MB, Pendleton RC, Segerson N, Cloward TV, Walker JM, Farney RJ, Gress RE, Adams TD, Hunt SC, Litwin SE. Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah obesity study. J Am Coll Cardiol. 2011;57:732 739. doi: 10.1016/j.jacc.2010.10.017. 233. Malone S, Liu PP, Holloway R, Rutherford R, Xie A, Bradley TD. Obstructive sleep apnoea in patients with dilated cardiomy- opathy: effects of continuous positive airway pressure. Lancet. 1991;338:1480 1484. 234. Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med. 2004;169:361 366. doi: 10.1164/rccm.200306-752OC. 235. Butt M, Dwivedi G, Shantsila A, Khair OA, Lip GYH. Left ventricu- lar systolic and diastolic function in obstructive sleep apnea: impact of continuous positive airway pressure therapy. Circ Heart Failure 2012;5:226 233. doi: 10.1161/CIRCHEARTFAILURE.111.964106. 236. Colish J, Walker JR, Elmayergi N, Almutairi S, Alharbi F, Lytwyn M, Francis A, Bohonis S, Zeglinski M, Kirkpatrick ID, Sharma S, Jassal DS. Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. Chest. 2012;141:674 681. doi: 10.1378/chest.11-0615. 237. Peters CM, O Neill JO, Young JB, Bott-Silverman C. Is there an association between ephedra and heart failure? A case series. J Card Fail. 2005;11:9 11. 238. Sayin T, G ldal M. Sibutramine: possible cause of a reversible car- diomyopathy. Int J Cardiol. 2005;99:481 482. doi: 10.1016/j. ijcard.2003.11.060. 239. Evangelista LS, Heber D, Li Z, Bowerman S, Hamilton MA, Fonarow GC. Reduced body weight and adiposity with a high-protein diet im- provesfunctionalstatus,lipidprofiles,glycemiccontrol,andqualityof life in patients with heart failure: a feasibility study. J Cardiovasc Nurs. 2009;24:207 215. doi: 10.1097/JCN.0b013e31819846b9. 240. Pritchett AM, Deswal A, Aguilar D, Foreyt JP, Chan W, Mann DL, Ballantyne C, Bozkurt B. Lifestyle modification with diet and exer- ciseinobesepatientswithheartfailure:apilotstudy.JObesWeight Loss Ther. 2012;2:1 8. doi: 10.4172/2165-7904.1000118. 241. Flynn KE, Pi a IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG, Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, O Connor CM, Weinfurt KP; HF-ACTION Investigators. Effects of exercise training on health status in pa- tients with chronic heart failure: HF-ACTION randomized controlled trial [published correction appears in JAMA. 2009;302:2322]. JAMA. 2009;301:1451 1459. doi: 10.1001/jama.2009.457. Management of Comorbidities in Chronic Heart Failure CLINICAL STATEMENTS AND GUIDELINES 242. FDA approves lorcaserin for the treatment of obesity. 2012. http:// www.theheart.org/article/1420361.do. Accessed July 2, 2012. 243. Ramani GV, McCloskey C, Ramanathan RC, Mathier MA. Safety and efficacy of bariatric surgery in morbidly obese patients with severe systolic heart failure. Clin Cardiol. 2008;31:516 520. doi: 10.1002/clc.20315. 244. Ristow B, Rabkin J, Haeusslein E. Improvement in dilated cardio- myopathy after bariatric surgery. J Card Fail. 2008;14:198 202. doi: 10.1016/j.cardfail.2007.12.006. 245. FDA approves weight-management drug Qsymia [news re- lease]. Bethesda, MD: US Food and Drug Administration. http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm312468.htm. Accessed July 12, 2012. 246. Beck-da-Silva L, Higginson L, Fraser M, Williams K, Haddad H. Effect of Orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail. 2005;11:118 123. 247. Weber MA, Neutel JM, Smith DH. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. J Am Coll Cardiol. 2001;37:169 174. 248. Kardassis D, Bech-Hanssen O, Sch nander M, Sj str m L, Petzold M, Karason K. Impact of body composition, fat distribution and sustained weight loss on cardiac function in obesity. Int J Cardiol. 2012;159:128 133. doi: 10.1016/j.ijcard.2011.02.036. 249. Riegel B, Moser DK, Anker SD, Appel LJ, Dunbar SB, Grady KL, Gurvitz MZ, Havranek EP, Lee CS, Lindenfeld J, Peterson PN, Pressler SJ, Schocken DD, Whellan DJ; on behalf of the American Heart Association Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Nutrition, Physical Activity, and Metabolism, and Interdisciplinary Council on Quality of Care and Outcomes Research. State of the science: promoting self- care in persons with heart failure: a scientific statement from the American Heart Association. Circulation. 2009;120:1141 1163. doi: 10.1161/CIRCULATIONAHA.109.192628. 250. McCloskey CA, Ramani GV, Mathier MA, Schauer PR, Eid GM, Mattar SG, Courcoulas AP, Ramanathan R. Bariatric surgery im- proves cardiac function in morbidly obese patients with severe cardiomyopathy. Surg Obes Relat Dis. 2007;3:503 507. doi: 10.1016/j.soard.2007.05.006. 251. Evangelista LS, Moser DK, Westlake C, Hamilton MA, Fonarow GC, Dracup K. Impact of obesity on quality of life and depression in patients with heart failure. Eur J Heart Fail. 2006;8:750 755. doi: 10.1016/j.ejheart.2006.02.004. 252. Katz DA, McHorney CA, Atkinson RL. Impact of obesity on health- related quality of life in patients with chronic illness. J Gen Intern Med. 2000;15:789 796. 253. Barbour KA, Miller NH. Adherence to exercise training in heart failure: a review. Heart Fail Rev. 2008;13:81 89. doi: 10.1007/ s10741-007-9054-x. 254. Evangelista LS, Dracup K, Erickson V, McCarthy WJ, Hamilton MA, Fonarow GC. Validity of pedometers for measuring exercise adherence in heart failure patients. J Card Fail. 2005;11:366 371. 255. Edelmann F, Gelbrich G, D ngen HD, Fr hling S, Wachter R, Stahrenberg R, Binder L, T pper A, Lashki DJ, Schwarz S, Herrmann-Lingen C, L ffler M, Hasenfuss G, Halle M, Pieske B. Exercise training improves exercise capacity and diastolic func- tion in patients with heart failure with preserved ejection frac- tion: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol. 2011;58:1780 1791. doi: 10.1016/j.jacc.2011.06.054. 256. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single- blind trial. Circ Heart Fail. 2010;3:659 667. doi: 10.1161/ CIRCHEARTFAILURE.110.958785. 257. Gary RA, Sueta CA, Dougherty M, Rosenberg B, Cheek D, Preisser J, Neelon V, McMurray R. Home-based exercise improves functional performance and quality of life in women with diastolic heart failure. Heart Lung. 2004;33:210 218. 258. Taylor RS, Davies EJ, Dalal HM, Davis R, Doherty P, Cooper C, Holland DJ, Jolly K, Smart NA. Effects of exercise training for heart failure with preserved ejection fraction: a systematic review and meta-analysis of comparative studies. Int J Cardiol. 2011;162:6 13. doi: 10.1016/j.ijcard.2012.05.070. 259. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation scientific statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing [published correction appears in Circulation. 2009;31:e380]. Circulation. 2008;118:1080 1111. doi: 10.1161/CIRCULATIONAHA.107. 189375. 260. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ, O Connor GT, Boland LL, Schwartz JE, Samet JM. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001;163:19 25. doi: 10.1164/ ajrccm.163.1.2001008. 261. Javaheri S, Parker TJ, Liming JD, Corbett WS, Nishiyama H, Wexler L, Roselle GA. Sleep apnea in 81 ambulatory male patients with stable heart failure: types and their prevalences, consequences, and presentations. Circulation. 1998;97:2154 2159. 262. Chan J, Sanderson J, Chan W, Lai C, Choy D, Ho A, Leung R. Prevalence of sleep-disordered breathing in diastolic heart fail- ure. Chest. 1997;111:1488 1493. 263. Bitter T, Faber L, Hering D, Langer C, Horstkotte D, Oldenburg O. Sleep-disordered breathing in heart failure with normal left ven- tricular ejection fraction. Eur J Heart Fail. 2009;11:602 608. doi: 10.1093/eurjhf/hfp057. 264. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre- existing cardiovascular disease. N Engl J Med. 1990;322:1700 1707. doi: 10.1056/NEJM199006143222403. 265. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121(pt 1):951 957. 266. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low se- rum total cholesterol is associated with marked increase in mor- tality in advanced heart failure. J Card Fail. 2002;8:216 224. 267. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, Coats AJ, Anker SD. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42:1933 1940. 268. Afsarmanesh N, Horwich TB, Fonarow GC. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J. 2006;152:1077 1083. doi: 10.1016/j.ahj.2006.06.015. 269. Horwich TB, Hernandez AF, Dai D, Yancy CW, Fonarow GC. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J. 2008;156:1170 1176. doi: 10.1016/j.ahj.2008.07.004. 270. Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, Krumholz HM. Statins and mortality among elderly patients hos- pitalized with heart failure. Circulation. 2006;113:1086 1092. doi: 10.1161/CIRCULATIONAHA.105.591446. 271. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93:1124 1129. doi: 10.1016/j.amjcard.2004.01.039. 272. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Py r l K. The effects of simvastatin on the incidence of heart failure in pa- tients with coronary heart disease [published correction appears in J Card Fail. 1998;4:367]. J Card Fail. 1997;3:249 254. Bozkurt et al 273. Kjekshus J, Apetrei E, Barrios V, B hm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, J nosi A, Kamensk G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older pa- tients with systolic heart failure. N Engl J Med. 2007;357:2248 2261. doi: 10.1056/NEJMoa0706201. 274. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI- HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231 1239. doi: 10.1016/S0140-6736(08)61240-4. 275. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA. AHA/ACCF secondary pre- vention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation [published correction appears in Circulation. 2015;131:e408]. Circulation. 2011;124:2458 2473. doi: 10.1161/CIR.0b013e318235eb4d. 276. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143 3421. 277. Macchia A, Levantesi G, Franzosi MG, Geraci E, Maggioni AP, Marfisi R, Nicolosi GL, Schweiger C, Tavazzi L, Tognoni G, Valagussa F, Marchioli R; GISSI-Prevenzione Investigators. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 poly- unsaturated fatty acids. Eur J Heart Fail. 2005;7:904 909. doi: 10.1016/j.ejheart.2005.04.008. 278. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in pa- tients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223 1230. doi: 10.1016/S0140-6736(08)61239-8. 279. Marchioli R, Levantesi G, Macchia A, Maggioni AP, Marfisi RM, Silletta MG, Tavazzi L, Tognoni G, Valagussa F; GISSI- Prevenzione Investigators. Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial. J Membr Biol. 2005;206:117 128. doi: 10.1007/s00232-005-0788-x. 280. Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M; GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosu- vastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6:635 641. doi: 10.1016/j.ejheart.2004.03.001. 281. Dietary supplementation with n-3 polyunsaturated fatty acids and vi- tamin E after myocardial infarction: results of the GISSI-Prevenzione trial: Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto miocardico [published corrections appear in Lancet. 2001;357:642 and Lancet. 2007;369:106]. Lancet. 1999;354:447 455. 282. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E; PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitaliza- tion for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study [published correction appears in J Am Coll Cardiol. 2013;62:1727]. J Am Coll Cardiol. 2006;47:2326 2331. doi: 10.1016/j.jacc.2006.03.034. 283. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. 2007;93:914 921. doi: 10.1136/hrt.2006.112508. 284. Strandberg TE, Holme I, Faergeman O, Kastelein JJ, Lindahl C, Larsen ML, Olsson AG, Pedersen TR, Tikkanen MJ; IDEAL Study Group. Comparative effect of atorvastatin (80 mg) versus simv- astatin (20 to 40 mg) in preventing hospitalizations for heart fail- ure in patients with previous myocardial infarction. Am J Cardiol. 2009;103:1381 1385. doi: 10.1016/j.amjcard.2009.01.377. 285. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001 1009. doi: 10.1056/NEJM199610033351401. 286. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011:CD004816. 287. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539 553. doi: 10.1002/ (SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. 288. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237 252. 289. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the meta- bolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published cor- rections appear in Circulation. 2005;112:e297 and Circulation. 10.1161/CIRCULATIONAHA.105.169404. 290. Zimmet P, Alberti G, Shaw J. A new IDF worldwide definition of the metabolic syndrome: the rationale and the results. Diabetes Voice. 2005;50:31 33. 291. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640 1645. doi: 10.1161/CIRCULATIONAHA.109.192644. 292. Li C, Ford ES, McGuire LC, Mokdad AH. Association of metabolic syndrome and insulin resistance with congestive heart failure: findings from the Third National Health and Nutrition Examination Survey. J Epidemiol Community Health. 2007;61:67 73. doi: 10.1136/jech.2006.048173. 293. Ingelsson E, Arnl v J, Lind L, Sundstr m J. Metabolic syn- drome and risk for heart failure in middle-aged men. Heart. 2006;92:1409 1413. doi: 10.1136/hrt.2006.089011. 294. Wang J, Sarnola K, Ruotsalainen S, Moilanen L, Lepist P, Laakso M, Kuusisto J. The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns. Atherosclerosis. 2010;210:237 242. doi: 10.1016/j. atherosclerosis.2009.10.042. 295. Suzuki T, Katz R, Jenny NS, Zakai NA, LeWinter MM, Barzilay JI, Cushman M. Metabolic syndrome, inflammation, and in- cident heart failure in the elderly: the Cardiovascular Health Study. Circ Heart Fail. 2008;1:242 248. doi: 10.1161/ CIRCHEARTFAILURE.108.785485. 296. Hassan SA, Deswal A, Bozkurt B, Aguilar D, Mann DL, Pritchett AM. The metabolic syndrome and mortality in an ethnically Management of Comorbidities in Chronic Heart Failure CLINICAL STATEMENTS AND GUIDELINES diverse heart failure population. J Card Fail. 2008;14:590 595. doi: 10.1016/j.cardfail.2008.03.004. 297. Tamariz L, Hassan B, Palacio A, Arcement L, Horswell R, Hebert K. Metabolic syndrome increases mortality in heart failure. Clin Cardiol. 2009;32:327 331. doi: 10.1002/clc.20496. 298. Miura Y, Fukumoto Y, Shiba N, Miura T, Shimada K, Iwama Y, Takagi A, Matsusaka H, Tsutsumi T, Yamada A, Kinugawa S, Asakura M, Okamatsu S, Tsutsui H, Daida H, Matsuzaki M, Tomoike H, Shimokawa H. Prevalence and clinical implication of metabolic syndrome in chronic heart failure. Circ J. 2010;74:2612 2621. 299. Karadag MK, Akbulut M. Low HDL levels as the most common metabolic syndrome risk factor in heart failure. Int Heart J. 2009;50:571 580. 300. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study Group. Prevalence of the meta- bolic syndrome and its relation to all-cause and cardiovas- cular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066 1076. doi: 10.1001/ archinte.164.10.1066. 301. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709 2716. 302. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/ American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551 556. doi: 10.1161/01.CIR.0000112379.88385.67. 303. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393 403. doi: 10.1056/NEJMoa012512. 304. Estruch R, Ros E, Salas-Salvad J, Covas MI, Corella D, Ar s F, G mez-Gracia E, Ruiz-Guti rrez V, Fiol M, Lapetra J, Lamuela- Raventos RM, Serra-Majem L, Pint X, Basora J, Mu oz MA, Sorl JV, Mart nez JA, Mart nez-Gonz lez MA; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279 1290. doi: 10.1056/NEJMoa1200303. 305. Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol. 2011;57:1299 1313. doi: 10.1016/j.jacc.2010.09.073. 306. Djouss L, Driver JA, Gaziano JM. Relation between modifi- able lifestyle factors and lifetime risk of heart failure. JAMA. 2009;302:394 400. doi: 10.1001/jama.2009.1062. 307. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383 393. doi: 10.1056/NEJMoa021778. 308. Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, Kahn SE, Knowler WC, Yanovski SZ; Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the pre- vention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24:610 628. 309. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes [published correction appears in N Engl J Med. 2014;370:1866]. N Engl J Med. 2013;369:145 154. 310. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566 1575. 311. Patel K, Sui X, Zhang Y, Fonarow GC, Aban IB, Brown CJ, Bittner V, Kitzman DW, Allman RM, Banach M, Aronow WS, Anker SD, Blair SN, Ahmed A. Prevention of heart failure in older adults may require higher levels of physical activity than needed for other cardiovascular events. Int J Cardiol. 2013;168:1905 1909. doi: 10.1016/j.ijcard.2012.12.053. 312. Rahman I, Bellavia A, Wolk A. Relationship between physical activ- ity and heart failure risk in women. Circ Heart Fail. 2014;7:877 881. doi: 10.1161/CIRCHEARTFAILURE.114.001467. 313. Wang Y, Tuomilehto J, Jousilahti P, Antikainen R, M h nen M, Katzmarzyk PT, Hu G. Occupational, commuting, and leisure- time physical activity in relation to heart failure among Finnish men and women. J Am Coll Cardiol. 2010;56:1140 1148. doi: 10.1016/j.jacc.2010.05.035. 314. Young DR, Reynolds K, Sidell M, Brar S, Ghai NR, Sternfeld B, Jacobsen SJ, Slezak JM, Caan B, Quinn VP. Effects of physi- cal activity and sedentary time on the risk of heart failure. Circ Heart Fail. 2014;7:21 27. doi: 10.1161/CIRCHEARTFAILURE. 113.000529. 315. Farrell SW, Finley CE, Radford NB, Haskell WL. Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study. Circ Heart Fail. 2013;6:898 905. doi: 10.1161/CIRCHEARTFAILURE.112.000088. 316. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancey AK, Wenger NK. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107:3109 3116. doi: 10.1161/01. CIR.0000075572.40158.77. 317. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, B hm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, K ber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, R nnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC guide- lines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology [published correction appears in Eur Heart J. 2013;34:158]. Eur Heart J. 2012;33:1787 1847. doi: 10.1093/eurheartj/ehs104. 318. Piepoli MF, Conraads V, Corr U, Dickstein K, Francis DP, Jaarsma T, McMurray J, Pieske B, Piotrowicz E, Schmid JP, Anker SD, Solal AC, Filippatos GS, Hoes AW, Gielen S, Giannuzzi P, Ponikowski PP. Exercise training in heart failure: from theory to practice. a consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail. 2011;13:347 357. doi: 10.1093/eurjhf/hfr017. 319. Davies EJ, Moxham T, Rees K, Singh S, Coats AJ, Ebrahim S, Lough F, Taylor RS. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail. 2010;12:706 715. doi: 10.1093/eurjhf/hfq056. 320. McKelvie RS. Exercise training in patients with heart failure: clinical outcomes, safety, and indications. Heart Fail Rev. 2008;13:3 11. doi: 10.1007/s10741-007-9052-z. Bozkurt et al 321. Levitan EB, Wolk A, Mittleman MA. Consistency with the DASH diet and incidence of heart failure. Arch Intern Med. 2009;169:851 857. doi: 10.1001/archinternmed.2009.56. 322. Levitan EB, Wolk A, Mittleman MA. Relation of consistency with the Dietary Approaches to Stop Hypertension diet and incidence of heart failure in men aged 45 to 79 years. Am J Cardiol. 2009;104:1416 1420. doi: 10.1016/j.amjcard.2009.06.061. 323. Fit M, Estruch R, Salas-Salvad J, Mart nez-Gonzalez MA, Ar s F, Vila J, Corella D, D az O, S ez G, de la Torre R, Mitjavila MT, Mu oz MA, Lamuela-Ravent s RM, Ruiz-Gutierrez V, Fiol M, G mez-Gracia E, Lapetra J, Ros E, Serra-Majem L, Covas MI; PREDIMED Study Investigators. Effect of the Mediterranean diet on heart failure bio- markers: a randomized sample from the PREDIMED trial. Eur J Heart Fail. 2014;16:543 550. doi: 10.1002/ejhf.61. 324. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardio- vascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99:779 785. 325. Levitan EB, Lewis CE, Tinker LF, Eaton CB, Ahmed A, Manson JE, Snetselaar LG, Martin LW, Trevisan M, Howard BV, Shikany JM. Mediterranean and DASH diet scores and mortality in women with heart failure: the Women s Health Initiative. Circ Heart Fail. 2013;6:1116 1123. doi: 10.1161/ CIRCHEARTFAILURE.113.000495. 326. Chrysohoou C, Pitsavos C, Metallinos G, Antoniou C, Oikonomou E, Kotroyiannis I, Tsantilas A, Tsitsinakis G, Tousoulis D, Panagiotakos DB, Stefanadis C. Cross-sectional relationship of a Mediterranean type diet to diastolic heart function in chronic heart failure patients. Heart Vessels. 2012;27:576 584. doi: 10.1007/s00380-011-0190-9. 327. Hummel SL, Seymour EM, Brook RD, Kolias TJ, Sheth SS, Rosenblum HR, Wells JM, Weder AB. Low-sodium Dietary Approaches to Stop Hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension. 2012;60:1200 1206. doi: 10.1161/HYPERTENSIONAHA.112.202705. 328. Hummel SL, Seymour EM, Brook RD, Sheth SS, Ghosh E, Zhu S, Weder AB, Kov cs SJ, Kolias TJ. Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection frac- tion. Circ Heart Fail. 2013;6:1165 1171. doi: 10.1161/ CIRCHEARTFAILURE.113.000481. 329. Van Horn L, Yancy C. Diet prevention and therapy for heart failure? Circ Heart Fail. 2013;6:1109 1111. doi: 10.1161/ CIRCHEARTFAILURE.113.000868. 330. Ribeiro RF Jr, Dabkowski ER, O Connell KA, Xu W, Galvao Tde F, Hecker PA, Shekar KC, Stefanon I, Stanley WC. Effect of a high-protein diet on development of heart failure in response to pressure overload. Appl Physiol Nutr Metab. 2014;39:238 247. doi: 10.1139/apnm-2013-0274. 331. Motie M, Evangelista LS, Horwich T, Hamilton M, Lombardo D, Cooper DM, Galassetti PR, Fonarow GC. Pro-HEART: a random- ized clinical trial to test the effectiveness of a high protein diet targeting obese individuals with heart failure: rationale, design and baseline characteristics. Contemp Clin Trials. 2013;36:371 381. doi: 10.1016/j.cct.2013.08.004. 332. Smart N, Haluska B, Jeffriess L, Marwick TH. Exercise train- ing in systolic and diastolic dysfunction: effects on cardiac function, functional capacity, and quality of life. Am Heart J. 2007;153:530 536. doi: 10.1016/j.ahj.2007.01.004. 333. Piepoli MF, Davos C, Francis DP, Coats AJ; ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004;328:189. doi: 10.1136/bmj.37938.645220.EE. 334. Meyer K, Samek L, Schwaibold M, Westbrook S, Hajric R, Lehmann M, Essfeld D, Roskamm H. Physical responses to different modes of interval exercise in patients with chronic heart failure: application to exercise training. Eur Heart J. 1996;17:1040 1047. 335. Pi a IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD, Fletcher BJ, Fleg JL, Myers JN, Sullivan MJ. Exercise and heart failure: a statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention. Circulation. 2003;107:1210 1225. 336. Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, Froelicher VF, Leon AS, Pi a IL, Rodney R, Simons-Morton DA, Williams MA, Bazzarre T. Exercise standards for testing and train- ing: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:1694 1740. 337. Haskell WL. The efficacy and safety of exercise programs in car- diac rehabilitation. Med Sci Sports Exerc. 1994;26:815 823. 338. Hare DL, Ryan TM, Selig SE, Pellizzer AM, Wrigley TV, Krum H. Resistance exercise training increases muscle strength, endur- ance, and blood flow in patients with chronic heart failure. Am J Cardiol. 1999;83:1674 1677, A7. 339. Maiorana A, O Driscoll G, Cheetham C, Collis J, Goodman C, Rankin S, Taylor R, Green D. Combined aerobic and resistance exercise training improves functional capacity and strength in CHF. J Appl Physiol (1985). 2000;88:1565 1570. 340. Pollock ML, Franklin BA, Balady GJ, Chaitman BL, Fleg JL, Fletcher B, Limacher M, Pi a IL, Stein RA, Williams M, Bazzarre T. AHA science advisory: resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation. 2000;101:828 833. 341. Dunbar SB, Butts B, Reilly CM, Gary RA, Higgins MK, Ferranti EP, Culler SD, Butler J. A pilot test of an integrated self-care intervention for persons with heart failure and concomitant diabetes. Nurs Outlook. 2014;62:97 111. doi: 10.1016/j. outlook.2013.09.003. 342. Wald NJ, Law MR. A strategy to reduce cardiovascular dis- ease by more than 80% [published corrections appear in BMJ. 2003;327:586 and BMJ. 2006;60:823]. BMJ. 2003;326:1419. doi: 10.1136/bmj.326.7404.1419. 343. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [pub- lished correction appears in Lancet. 2003;361:1060]. Lancet. 2002;360:1903 1913. 344. American Heart Association. American Heart Association s Life s Simple 7 Tool Kit Web link. http://mylifecheck.heart.org/. Accessed April 17, 2013. 345. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD; on behalf of the American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduc- tion: the American Heart Association s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121:586 613. doi: 10.1161/CIRCULATIONAHA.109.192703.